Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome

Bixin Xi; Chen Zhou; Yu Zhang

doi:10.1002/ccr3.4111

Clinical Case Reports (May 2021)

Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome

Bixin Xi,
Chen Zhou,
Yu Zhang

Affiliations

Bixin Xi: Department of Paediatrics Tongji HospitalTongji Medical CollegeHuazhong University of Science and Technology Wuhan China
Chen Zhou: Key Laboratory of Paediatric Haematology and Oncology Ministry of Health Department of Haematology and Oncology Shanghai Children's Medical Centre Shanghai Jiao Tong University School of Medicine Shanghai China
Yu Zhang: Department of Gynaecology Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital)Tongji Medical CollegeHuazhong University of Science and Technology Wuhan China

DOI: https://doi.org/10.1002/ccr3.4111
Journal volume & issue: Vol. 9, no. 5
pp. n/a – n/a

Abstract

Read online

Abstract We report the first case of a 12‐year‐old boy with Wiskott‐Aldrich syndrome who developed CD20‐weakly expressed and CD30‐highly expressed Epstein‐Barr virus–related post‐transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated with personalized low‐dose chemotherapy and subsequently remained in complete remission for 1 year.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0904

About the journal

Abstract

Keywords